FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:ABTB2-APIP

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: ABTB2-APIP
FusionPDB ID: 568
FusionGDB2.0 ID: 568
HgeneTgene
Gene symbol

ABTB2

APIP

Gene ID

25841

51074

Gene nameankyrin repeat and BTB domain containing 2APAF1 interacting protein
SynonymsABTB2A|BTBD22APIP2|CGI-29|CGI29|MMRP19|hAPIP
Cytomap

11p13

11p13

Type of geneprotein-codingprotein-coding
Descriptionankyrin repeat and BTB/POZ domain-containing protein 2ankyrin repeat and BTB (POZ) domain containing 2methylthioribulose-1-phosphate dehydrataseMTRu-1-P dehydrataseprobable methylthioribulose-1-phosphate dehydratase
Modification date2020031320200327
UniProtAcc

Q8N961

Main function of 5'-partner protein: FUNCTION: May be involved in the initiation of hepatocyte growth. {ECO:0000250}.

Q96GX9

Main function of 5'-partner protein: FUNCTION: Catalyzes the dehydration of methylthioribulose-1-phosphate (MTRu-1-P) into 2,3-diketo-5-methylthiopentyl-1-phosphate (DK-MTP-1-P). Functions in the methionine salvage pathway, which plays a key role in cancer, apoptosis, microbial proliferation and inflammation. May inhibit the CASP1-related inflammatory response (pyroptosis), the CASP9-dependent apoptotic pathway and the cytochrome c-dependent and APAF1-mediated cell death. {ECO:0000255|HAMAP-Rule:MF_03116, ECO:0000269|PubMed:15262985, ECO:0000269|PubMed:22837397, ECO:0000269|PubMed:23285211, ECO:0000269|PubMed:24367089}.
Ensembl transtripts involved in fusion geneENST idsENST00000298992, ENST00000435224, 
ENST00000530814, 
ENST00000527830, 
ENST00000278359, ENST00000395787, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score13 X 10 X 3=3902 X 2 X 3=12
# samples 163
** MAII scorelog2(16/390*10)=-1.28540221886225
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(3/12*10)=1.32192809488736
effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs).
DoF>8 and MAII>0
Fusion gene context

PubMed: ABTB2 [Title/Abstract] AND APIP [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: ABTB2 [Title/Abstract] AND APIP [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)ABTB2(34186233)-APIP(34916657), # samples:2
Anticipated loss of major functional domain due to fusion event.ABTB2-APIP seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
ABTB2-APIP seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
ABTB2-APIP seems lost the major protein functional domain in Tgene partner, which is a cell metabolism gene due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
TgeneAPIP

GO:0051289

protein homotetramerization

24367089



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr11:34186233/chr11:34916657)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across ABTB2 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across APIP (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000298992ABTB2chr1134378248-ENST00000278359APIPchr1134916657-13635554261226266
ENST00000298992ABTB2chr1134378248-ENST00000395787APIPchr1134916657-16495554261226266
ENST00000435224ABTB2chr1134378248-ENST00000278359APIPchr1134916657-21161308591396445
ENST00000435224ABTB2chr1134378248-ENST00000395787APIPchr1134916657-24021308591396445

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000298992ENST00000278359ABTB2chr1134378248-APIPchr1134916657-0.004026920.99597305
ENST00000298992ENST00000395787ABTB2chr1134378248-APIPchr1134916657-0.0016338850.9983662
ENST00000435224ENST00000278359ABTB2chr1134378248-APIPchr1134916657-0.162574830.8374252
ENST00000435224ENST00000395787ABTB2chr1134378248-APIPchr1134916657-0.1292440.870756

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for ABTB2-APIP

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
ABTB2chr1134378248APIPchr11349166571308416QPYEHLICGKNANGQGASKIPDPRTL
ABTB2chr1134378248APIPchr113491665755543SPMSISSAARTPMDKEHPRYLIPELC

Top

Potential FusionNeoAntigen Information of ABTB2-APIP in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
ABTB2-APIP_34378248_34916657.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
ABTB2-APIPchr1134378248chr1134916657555HLA-B35:08TPMDKEHPRY0.99630.91131020
ABTB2-APIPchr1134378248chr1134916657555HLA-B35:01TPMDKEHPRY0.99610.9291020
ABTB2-APIPchr1134378248chr1134916657555HLA-B35:05TPMDKEHPRY0.97170.72561020
ABTB2-APIPchr1134378248chr1134916657555HLA-A74:03RTPMDKEHPR0.93640.7881919
ABTB2-APIPchr1134378248chr1134916657555HLA-A74:09RTPMDKEHPR0.93640.7881919
ABTB2-APIPchr1134378248chr1134916657555HLA-A74:11RTPMDKEHPR0.93640.7881919
ABTB2-APIPchr1134378248chr1134916657555HLA-A31:02RTPMDKEHPR0.930.8046919
ABTB2-APIPchr1134378248chr1134916657555HLA-A31:06RTPMDKEHPR0.71990.6663919
ABTB2-APIPchr1134378248chr1134916657555HLA-B35:03TPMDKEHPRYL0.97460.9351021
ABTB2-APIPchr1134378248chr1134916657555HLA-B35:02TPMDKEHPRYL0.93330.94851021
ABTB2-APIPchr1134378248chr1134916657555HLA-B35:04TPMDKEHPRYL0.93330.94851021
ABTB2-APIPchr1134378248chr1134916657555HLA-B15:31TPMDKEHPRY0.99560.89661020
ABTB2-APIPchr1134378248chr1134916657555HLA-A31:01RTPMDKEHPR0.95160.7783919
ABTB2-APIPchr1134378248chr1134916657555HLA-B07:12TPMDKEHPRYL0.99880.69521021
ABTB2-APIPchr1134378248chr1134916657555HLA-B35:12TPMDKEHPRYL0.93330.94851021
ABTB2-APIPchr1134378248chr1134916657555HLA-B39:10TPMDKEHPRYL0.88340.91031021
ABTB2-APIPchr1134378248chr1134916657555HLA-B08:12MDKEHPRYL0.78560.63571221
ABTB2-APIPchr1134378248chr1134916657555HLA-B35:77TPMDKEHPRY0.99610.9291020
ABTB2-APIPchr1134378248chr1134916657555HLA-B35:23TPMDKEHPRY0.99570.9291020
ABTB2-APIPchr1134378248chr1134916657555HLA-B35:20TPMDKEHPRY0.99550.91821020
ABTB2-APIPchr1134378248chr1134916657555HLA-B35:17TPMDKEHPRY0.98610.84941020
ABTB2-APIPchr1134378248chr1134916657555HLA-B35:30TPMDKEHPRY0.98610.84941020
ABTB2-APIPchr1134378248chr1134916657555HLA-B35:24TPMDKEHPRY0.98550.94151020
ABTB2-APIPchr1134378248chr1134916657555HLA-B35:11TPMDKEHPRY0.97960.92761020
ABTB2-APIPchr1134378248chr1134916657555HLA-B15:08TPMDKEHPRY0.94360.88021020
ABTB2-APIPchr1134378248chr1134916657555HLA-B15:11TPMDKEHPRY0.94270.88291020
ABTB2-APIPchr1134378248chr1134916657555HLA-A74:01RTPMDKEHPR0.93640.7881919
ABTB2-APIPchr1134378248chr1134916657555HLA-B35:43TPMDKEHPRY0.92730.88231020
ABTB2-APIPchr1134378248chr1134916657555HLA-B18:07TPMDKEHPRY0.44660.89431020
ABTB2-APIPchr1134378248chr1134916657555HLA-B08:12TPMDKEHPRYL0.98450.64551021
ABTB2-APIPchr1134378248chr1134916657555HLA-B35:09TPMDKEHPRYL0.93330.94851021
ABTB2-APIPchr1134378248chr1134916657555HLA-B67:01TPMDKEHPRYL0.89550.78531021

Top

Potential FusionNeoAntigen Information of ABTB2-APIP in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
ABTB2-APIP_34378248_34916657.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
ABTB2-APIPchr1134378248chr1134916657555DRB1-1117PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1117SPMSISSAARTPMDK015
ABTB2-APIPchr1134378248chr1134916657555DRB1-1152PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1152SPMSISSAARTPMDK015
ABTB2-APIPchr1134378248chr1134916657555DRB1-1189PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1189SPMSISSAARTPMDK015
ABTB2-APIPchr1134378248chr1134916657555DRB1-1354PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1376PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1401PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1401SPMSISSAARTPMDK015
ABTB2-APIPchr1134378248chr1134916657555DRB1-1404PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1404SPMSISSAARTPMDK015
ABTB2-APIPchr1134378248chr1134916657555DRB1-1405PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1405SPMSISSAARTPMDK015
ABTB2-APIPchr1134378248chr1134916657555DRB1-1407PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1408PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1408SPMSISSAARTPMDK015
ABTB2-APIPchr1134378248chr1134916657555DRB1-1411PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1411SPMSISSAARTPMDK015
ABTB2-APIPchr1134378248chr1134916657555DRB1-1414PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1418PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1418SPMSISSAARTPMDK015
ABTB2-APIPchr1134378248chr1134916657555DRB1-1423PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1423SPMSISSAARTPMDK015
ABTB2-APIPchr1134378248chr1134916657555DRB1-1426PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1426SPMSISSAARTPMDK015
ABTB2-APIPchr1134378248chr1134916657555DRB1-1428PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1428SPMSISSAARTPMDK015
ABTB2-APIPchr1134378248chr1134916657555DRB1-1431PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1432PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1432SPMSISSAARTPMDK015
ABTB2-APIPchr1134378248chr1134916657555DRB1-1433PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1433SPMSISSAARTPMDK015
ABTB2-APIPchr1134378248chr1134916657555DRB1-1434PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1434SPMSISSAARTPMDK015
ABTB2-APIPchr1134378248chr1134916657555DRB1-1435PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1435SPMSISSAARTPMDK015
ABTB2-APIPchr1134378248chr1134916657555DRB1-1436PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1438PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1438SPMSISSAARTPMDK015
ABTB2-APIPchr1134378248chr1134916657555DRB1-1439PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1439SPMSISSAARTPMDK015
ABTB2-APIPchr1134378248chr1134916657555DRB1-1443PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1443SPMSISSAARTPMDK015
ABTB2-APIPchr1134378248chr1134916657555DRB1-1444PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1445PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1445SPMSISSAARTPMDK015
ABTB2-APIPchr1134378248chr1134916657555DRB1-1450PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1450SPMSISSAARTPMDK015
ABTB2-APIPchr1134378248chr1134916657555DRB1-1454PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1454SPMSISSAARTPMDK015
ABTB2-APIPchr1134378248chr1134916657555DRB1-1455PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1455SPMSISSAARTPMDK015
ABTB2-APIPchr1134378248chr1134916657555DRB1-1456PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1456SPMSISSAARTPMDK015
ABTB2-APIPchr1134378248chr1134916657555DRB1-1458PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1458SPMSISSAARTPMDK015
ABTB2-APIPchr1134378248chr1134916657555DRB1-1459PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1459SPMSISSAARTPMDK015
ABTB2-APIPchr1134378248chr1134916657555DRB1-1460PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1460SPMSISSAARTPMDK015
ABTB2-APIPchr1134378248chr1134916657555DRB1-1461PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1461SPMSISSAARTPMDK015
ABTB2-APIPchr1134378248chr1134916657555DRB1-1462PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1462SPMSISSAARTPMDK015
ABTB2-APIPchr1134378248chr1134916657555DRB1-1464PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1464SPMSISSAARTPMDK015
ABTB2-APIPchr1134378248chr1134916657555DRB1-1470PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1470SPMSISSAARTPMDK015
ABTB2-APIPchr1134378248chr1134916657555DRB1-1471PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1471SPMSISSAARTPMDK015
ABTB2-APIPchr1134378248chr1134916657555DRB1-1472PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1472SPMSISSAARTPMDK015
ABTB2-APIPchr1134378248chr1134916657555DRB1-1473PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1475PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1475SPMSISSAARTPMDK015
ABTB2-APIPchr1134378248chr1134916657555DRB1-1480PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1481PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1482PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1482SPMSISSAARTPMDK015
ABTB2-APIPchr1134378248chr1134916657555DRB1-1486PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1486SPMSISSAARTPMDK015
ABTB2-APIPchr1134378248chr1134916657555DRB1-1487PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1487SPMSISSAARTPMDK015
ABTB2-APIPchr1134378248chr1134916657555DRB1-1488PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1488SPMSISSAARTPMDK015
ABTB2-APIPchr1134378248chr1134916657555DRB1-1490PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1490SPMSISSAARTPMDK015
ABTB2-APIPchr1134378248chr1134916657555DRB1-1491PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1491SPMSISSAARTPMDK015
ABTB2-APIPchr1134378248chr1134916657555DRB1-1495PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1495SPMSISSAARTPMDK015
ABTB2-APIPchr1134378248chr1134916657555DRB1-1496PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1496SPMSISSAARTPMDK015
ABTB2-APIPchr1134378248chr1134916657555DRB1-1497PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1497SPMSISSAARTPMDK015
ABTB2-APIPchr1134378248chr1134916657555DRB1-1499PMSISSAARTPMDKE116
ABTB2-APIPchr1134378248chr1134916657555DRB1-1499SPMSISSAARTPMDK015

Top

Fusion breakpoint peptide structures of ABTB2-APIP

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
8366SAARTPMDKEHPRYABTB2APIPchr1134378248chr1134916657555

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of ABTB2-APIP

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN8366SAARTPMDKEHPRY-7.15543-7.26883
HLA-B14:023BVN8366SAARTPMDKEHPRY-4.77435-5.80965
HLA-B52:013W398366SAARTPMDKEHPRY-6.80875-6.92215
HLA-B52:013W398366SAARTPMDKEHPRY-4.20386-5.23916
HLA-A11:014UQ28366SAARTPMDKEHPRY-7.5194-8.5547
HLA-A11:014UQ28366SAARTPMDKEHPRY-6.9601-7.0735
HLA-A24:025HGA8366SAARTPMDKEHPRY-7.52403-7.63743
HLA-A24:025HGA8366SAARTPMDKEHPRY-5.82433-6.85963
HLA-B27:056PYJ8366SAARTPMDKEHPRY-3.28285-4.31815
HLA-B44:053DX88366SAARTPMDKEHPRY-5.91172-6.94702
HLA-B44:053DX88366SAARTPMDKEHPRY-4.24346-4.35686

Top

Vaccine Design for the FusionNeoAntigens of ABTB2-APIP

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
ABTB2-APIPchr1134378248chr11349166571020TPMDKEHPRYACGCCAATGGACAAGGAGCATCCAAGATAC
ABTB2-APIPchr1134378248chr11349166571021TPMDKEHPRYLACGCCAATGGACAAGGAGCATCCAAGATACCTG
ABTB2-APIPchr1134378248chr11349166571221MDKEHPRYLATGGACAAGGAGCATCCAAGATACCTG
ABTB2-APIPchr1134378248chr1134916657919RTPMDKEHPRAGAACGCCAATGGACAAGGAGCATCCAAGA

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
ABTB2-APIPchr1134378248chr1134916657015SPMSISSAARTPMDKAGCCCTATGAGCATCTCATCTGCGGCAAGAACGCCAATGGACAAG
ABTB2-APIPchr1134378248chr1134916657116PMSISSAARTPMDKECCTATGAGCATCTCATCTGCGGCAAGAACGCCAATGGACAAGGAG

Top

Information of the samples that have these potential fusion neoantigens of ABTB2-APIP

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
STADABTB2-APIPchr1134378248ENST00000298992chr1134916657ENST00000278359TCGA-CG-4449-01A

Top

Potential target of CAR-T therapy development for ABTB2-APIP

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to ABTB2-APIP

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to ABTB2-APIP

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource